Interim Data from Sub-Q Therapy for VWD

Star Therapuetics has shared an update on its ongoing clinical trial of VGA039, an investigational therapy for von Willebrand disease. The therapy uses a monthly prophylactic dose delivered subcutaneously.  

Source: National Bleeding Disorders Foundation, NBDF Notes, December 2025